Complete remission of third recurrence of acute myeloid leukemia after treatment with Imatinib (STI-571)

被引:11
|
作者
Schittenhelm, M
Aichele, O
Kröber, SM
Brümmendorf, T
Kanz, L
Denzlinger, C [1 ]
机构
[1] Univ Tubingen, Dept Haematol Oncol, Sch Med, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
关键词
AML; c-kit; CD117; Imatinib; glivec; STI-571;
D O I
10.1080/1042819031000077034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the case of a 76-year old patient with third relapse of AML who was successfully treated with Imatinib. The decision to try Imatinib was guided by bright expression of c-kit on the patient's blasts. Treatment was well tolerated but the dose was reduced for pancytopenia and later stopped completely because of pneumonia. The patient recovered with i.v. antibiotics, antimycotics and s.c. G-CSF. Reevaluation of the bone marrow after the end of treatment demonstrated the absence of malignant blasts. Treatment with Imatinib was started again with the intention to prolong remission duration. During the following months peripheral blood counts stabilized in the normal range indicating that a fourth complete remission has been achieved in this patient. This is the first report demonstrating that Imatinib can induce complete remission in relapsed c-kit positive AML in an elderly patient. Prolonged cytopenia remains a considerable problem indicating that normal haematopoiesis is not completely independent of the signalling cascades inhibited by Imatinib. Nevertheless our report supports further study of this drug in c-kit positive AML.
引用
收藏
页码:1251 / 1253
页数:3
相关论文
共 50 条
  • [41] Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia
    Ebos, JML
    Tran, J
    Master, Z
    Dumont, D
    Melo, JV
    Buchdunger, E
    Kerbel, RS
    MOLECULAR CANCER RESEARCH, 2002, 1 (02) : 89 - 95
  • [42] Cytogenetic studies on a chronic myeloid leukemia case developing into acute myeloid leukemia after treatment with imatinib
    Kroes, Wilma
    den Ouden, Elke
    Kok, Edwin
    Kerkhoffs, Jean Louis
    CHROMOSOME RESEARCH, 2013, 21 : S85 - S85
  • [43] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Ishii
    Daigo Akahane
    Kousuke Nunoda
    Seiko Honda
    Tomoiku Takaku
    Kazuma Ohyashiki
    International Journal of Hematology, 2007, 85 : 173 - 174
  • [44] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Ishii, Yuko
    Akahane, Daigo
    Nunoda, Kousuke
    Honda, Seiko
    Takaku, Tomoiku
    Ohyashiki, Kazuma
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (02) : 173 - 174
  • [45] Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Kvasnicka, HM
    Thiele, J
    Staib, P
    Schmitt-Graeff, A
    Griesshammer, M
    Klose, J
    Engels, K
    Kriener, S
    BLOOD, 2004, 103 (09) : 3549 - 3551
  • [46] Stem cell collection in chronic myeloid leukemia patients with cytogenetic response to imatinib mesylate (STI 571, gleevec)
    Hardan, I
    Lennard, A
    Nagler, A
    Shimoni, A
    Sareli, R
    Boque, C
    Canzio, M
    Olavarria, E
    Niederwieser, D
    BONE MARROW TRANSPLANTATION, 2003, 31 : S62 - S62
  • [47] Marked regression of metastatic Pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): A case report and laboratory investigation
    McLaughlin, ME
    Robson, CD
    Kieran, MW
    Jacks, T
    Pomeroy, SL
    Cameron, S
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (08) : 644 - 648
  • [48] Anti-fibrogenic effect of the tyrosine kinase inhibitor STI-571 on bone marrow fibrosis in chronic myeloid leukemia.
    Boecklin, F
    Hasserjian, RP
    Olavarria, E
    Armstrong, L
    Mulvanny, M
    Eades, A
    Chase, A
    Bua, M
    Zaiac, M
    Apperley, J
    Goldman, JM
    BLOOD, 2000, 96 (11) : 734A - 734A
  • [49] Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage
    Goldberg, Z
    Levav, Y
    Krichevsky, S
    Fibach, E
    Haupt, Y
    CELL CYCLE, 2004, 3 (09) : 1188 - 1195
  • [50] Acute Myeloid Leukemia With Myeloid Sarcoma and Eosinophilia: Prolonged Remission and Molecular Response to Imatinib
    Vedy, Dana
    Muehlematter, Dominique
    Rausch, Thierry
    Stalder, Michele
    Jotterand, Martine
    Spertini, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : E33 - E35